Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| ASML Holding | 0.97% | $115.45M | $468.07B | 61.61% | 81 Outperform | |
| Roche Holding AG | 0.90% | $106.97M | CHF270.15B | 45.02% | 73 Outperform | |
| HSBC Holdings | 0.78% | $92.79M | $274.62B | 63.10% | 78 Outperform | |
| Shell | 0.74% | $88.49M | $202.84B | 8.64% | 78 Outperform | |
| Novartis | 0.68% | $81.18M | $270.27B | 41.15% | 80 Outperform | |
| SAFRAN SA | 0.60% | $71.74M | €132.74B | 45.68% | 67 Neutral | |
| UBS Group AG | 0.59% | $70.95M | $145.90B | 45.49% | ― | |
| Celestica | 0.54% | $64.43M | $35.14B | 178.46% | 73 Outperform | |
| Toyota Motor | 0.54% | $64.06M | $276.45B | 17.04% | 81 Outperform | |
| Barclays | 0.52% | $62.05M | $89.11B | 105.44% | 77 Outperform |